ZimVie stockholders approve acquisition by ARCHIMED affiliate.

ZimVie Inc. announced that its stockholders have approved the acquisition by an affiliate of ARCHIMED, with the merger expected to close on October 20, 2025, subject to certain conditions. ZimVie is a global life sciences leader in the dental implant market, developing, manufacturing, and delivering a range of products and solutions for tooth replacement and restoration procedures. The acquisition is expected to enhance ZimVie's position in the market and improve its offerings for dental professionals and patients.

PALM BEACH GARDENS, Fla., Oct. 10, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (“ZimVie”) (Nasdaq: ZIMV) today announced that at a special meeting of ZimVie stockholders held on October 10, 2025, the stockholders voted to approve the acquisition of ZimVie by an affiliate of ARCHIMED. The merger is expected to close on October 20, 2025, subject to the satisfaction of all conditions outlined in the Merger Agreement ZimVie Stockholders Vote to Approve Acquisition by ARCHIMED^[1].

ZimVie, a global leader in the dental implant market, specializes in developing, manufacturing, and delivering a comprehensive portfolio of products and solutions designed to support dental tooth replacement and restoration procedures. The company's headquarters are located in Palm Beach Gardens, Florida, with additional facilities around the globe. ZimVie aims to improve smiles, function, and confidence in daily life through its offerings, which include trusted dental implants, biomaterials, and digital workflow solutions ZimVie Stockholders Vote to Approve Acquisition by ARCHIMED^[1].

ARCHIMED, a leading investment firm focused exclusively on healthcare industries, has offices in Europe, North America, and Asia. With a mix of operational, medical, scientific, and financial expertise, ARCHIMED serves as both a strategic and financial partner to healthcare businesses. Prioritized areas of focus include Animal & Environmental Health, Biopharma Products, Consumer Health, Diagnostics, Healthcare IT, Life Science Tools & Biologic Services, MedTech, and Pharma Services. ARCHIMED manages €8 billion across its various funds and is committed to Impact investing ZimVie Stockholders Vote to Approve Acquisition by ARCHIMED^[1].

The acquisition is expected to enhance ZimVie's position in the market and improve its offerings for dental professionals and patients. The merger will bring together ZimVie's expertise in dental implants and ARCHIMED's extensive healthcare industry experience, potentially leading to innovative solutions and expanded market reach.

The transaction is subject to the satisfaction of certain conditions, including regulatory approvals and the fulfillment of various other requirements outlined in the Merger Agreement. The closing date is currently set for October 20, 2025 ZimVie Stockholders Vote to Approve Acquisition by ARCHIMED^[1].

For more information about ZimVie, please visit www.ZimVie.com. For more information about ARCHIMED, please visit www.archimed.group.